

Appendix 1 (as supplied by authors):

Table 1: Healthcare and Combined Oral Contraceptive Utilization at Baseline; Expanded Polycystic ovary Syndrome Definition		
	PCOS [†]	Matched Controls
Number of Women	84,632	84,632
Mean age, yr	29.4	29.3
Healthcare Utilization[‡]		
Hospitalization, %	3.32	4.14
ER Visit, %	3.91	3.91
Office Visit, %	50.93	50.11
Combined Oral Contraceptive Utilization		
New User, # (%)	39,163 (46.27)	39,405 (46.56)
Prevalent User, # (%)	45,469 (53.73)	45,227 (53.44)
Prior time on COCs, mean, d	107	105
Total time on COCs, mean, d	210	211
Number prior COC products, mean	0.6	0.6
Combined Oral Contraceptive Product		
Desogestrel, %		
EE 20µg	3.53	3.50
EE 25µg	0.46	0.48
EE 30µg	8.30	8.31
Drospirenone, %		
EE 20µg	7.01	7.16
EE 30µg	17.46	17.37
Levonorgestrel, %		
EE 20µg	5.66	5.76
EE 30µg	3.98	3.93
Triphasic	2.78	2.84
Norethindrone, %		
EE 35µg	10.64	10.56
Norethindrone acetate, %		
EE 20µg	4.68	4.80
EE 30µg	2.73	2.85
EE 35µg	1.60	1.46
Norgestimate, %		
EE 25µg	6.35	6.45
EE 35µg	20.26	19.97
Norgestrel, %		
EE 30µg	4.56	4.56

[†]PCOS defined as a claim for PCOS (ICD-9-CM 256.4), a claim for a PCOS diagnostic criteria [anovulation (ICD-9-CM 628.0) or hirsutism (ICD-9-CM 704.1)], or a prescription treatment for PCOS (spironolactone)

Table 2: Comparison of Medication Use and Comorbidities at Cohort Entry and Cohort End; Expanded Polycystic Ovary Syndrome Definition)

	Population Characteristics at Cohort Entry		Population Characteristics at Cohort End	
	PCOS†	Matched Controls	PCOS†	Matched Controls
Medications, %				
ACEI / ARB	1.79	1.92	4.16	3.81
Beta Blocker	3.05	3.16	7.45	6.18
Benzodiazepine	8.70	8.81	21.13	16.81
Calcium Channel	0.87	0.86	2.38	1.88
Diabetes Meds	10.39	10.07	23.92	10.99
SSRI/TCA	16.51	16.93	31.05	28.24
Statin/Fibrate	1.87	1.99	4.42	4.06
Comorbidities, %				
Acne	18.46	18.17	35.31	25.84
Asthma	5.99	6.26	13.68	12.01
COPD	2.94	2.96	10.30	8.58
Diabetes	4.48	4.94	9.96	7.89
Dysmenorrhea	5.53	5.70	13.55	10.87
Endometriosis	2.67	3.19	7.13	5.13
Hyperlipidemia	8.34	8.61	22.45	17.55
Hypertension	6.24	6.38	15.21	12.31
Hypothyroid	8.83	6.96	14.66	11.08
Ovarian Inflammation	1.63	2.02	5.20	3.84
Vaginal Inflammation	12.24	12.58	31.09	27.40
Uterine Leiomyoma	2.15	2.50	6.16	5.19
Menstrual Irregular	32.54	33.51	62.99	47.72
Migraine	5.25	5.29	14.29	12.04
Mood / Anxiety Dis.	15.02	15.41	32.63	28.68
Obesity	9.53	9.61	24.88	16.67
PUD	0.30	0.29	0.30	0.29
PTS (PMS/PMDD)	1.63	1.72	4.51	3.45
Sleep Disorder	0.60	0.58	2.49	1.49
Smoking	2.23	2.41	6.53	6.43

†PCOS defined as a claim for PCOS (ICD-9-CM 256.4), a claim for a PCOS diagnostic criteria [anovulation (ICD-9-CM 628.0) or hirsutism (ICD-9-CM 704.1)], or a prescription treatment for PCOS (spironolactone)